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Cumulative meta-analysisa b s t r a c t
Cumulative meta-analyses are used to evaluate the extent to which further studies are needed to conﬁrm
or refute a hypothesis. We used this approach to assess observational evidence on systemic inﬂammation
in individuals with major depressive disorder. We identiﬁed 58 studies of four common inﬂammatory
markers in a literature search of PubMed, Embase and PsychInfo databases in May 2014. Pooled data from
the earliest eight studies already showed an association between interleukin-6 concentrations and major
depression; 23 more recent studies conﬁrmed this ﬁnding (d = 0.54, p < 0.0001). A signiﬁcant association
between C-reactive protein levels and major depression was noted after 14 studies and this did not
change after addition of six more studies (d = 0.47, p < 0.0001). For these two inﬂammatory markers,
there was moderate heterogeneity in study-speciﬁc estimates, subgroup differences were small, and pub-
lication bias appeared to be an unlikely explanation for the ﬁndings. Sensitivity analyses including only
high-quality studies and subjects free of antidepressant medication further veriﬁed the associations.
While there was a link between tumour necrosis factor-a levels and major depression (d = 0.40,
p = 0.002), the cumulative effect remained uncertain due to the extensive heterogeneity in
study-speciﬁc estimates and inconsistencies between subgroups. No evidence was found for the associ-
ation between interleukin-1b levels and major depression (d = 0.05, p = 0.86). In conclusion, this cumu-
lative meta-analysis conﬁrmed higher mean levels of interleukin-6 and C-reactive protein in patients
with major depression compared to non-depressed controls. No consistent association between tumour
necrosis factor-a, interleukin-1b and major depression was observed. Future studies should clarify the
speciﬁc immune mechanisms involved as well as continue testing anti-inﬂammatory therapies in
patients suffering from major depression.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Major depressive disorder (MDD) is a leading cause of disability
and an important contributing factor to the worldwide burden of
disease; it can directly cause mortality due to suicide and indi-
rectly through affecting prognosis of chronic conditions such as
ischemic heart disease (Whiteford et al., 2013). The inﬂammation
hypothesis of depression proposes that MDD is also associatedwith sustained activation of the innate immune system leading
to increased production of proinﬂammatory cytokines and acute
phase proteins (Maes, 1995; Smith, 1991). In support of this
hypothesis, several studies have detected higher levels of inﬂam-
mation in depressed individuals than in healthy controls, although
the strength of evidence varies depending on which speciﬁc
inﬂammatory markers have been examined, i.e. interleukin (IL)-6,
IL-1b, tumour necrosis factor (TNF)-a and C-reactive protein
(CRP) (Dowlati et al., 2010; Hiles et al., 2012b; Howren et al.,
2009; Liu et al., 2012; Valkanova et al., 2013).
In a cumulative meta-analysis, the results from individual stud-
ies are added chronologically and the aggregate effect estimate
recomputed after addition of each study. The purpose of this
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ried out in a similar manner are unlikely to change the conclusion.
Importantly, information in these analyses may help researchers to
justify additional studies or to become aware of the need for redi-
recting their research efforts (Clarke et al., 2014). Here, we have
applied this approach to evaluate the strength of the association
between speciﬁc inﬂammatory markers (IL-6, IL-1b, CRP-a, TNF)
and MDD.2. Materials and methods
2.1. Literature search and data extraction
We performed a systematic search of the literature using
PubMed, Embase, PsychInfo to include publications until May
2014 with the following search terms: [‘‘depression’’], [‘‘depres-
sive’’], [‘‘C-reactive protein’’], [‘‘CRP’’], [‘‘interleukin 6’’], [‘‘IL-6’’],
[‘‘tumour necrosis factor a’’], [TNF-alpha’’], [‘‘interleukin 1b’’],
[IL-1beta’’], [‘‘cytokine’’]. We also scrutinised the reference lists of
all of the relevant publications identiﬁed. In addition, we used
the Institute of Scientiﬁc Information Web of Science (May 2014)
to retrieve all the studies citing the studies identiﬁed by the search.
Information from the articles included in the meta-analysis report-
ing an association between CRP (Howren et al., 2009), IL-6, TNF-a,
IL-1b (Dowlati et al., 2010; Hiles et al., 2012b; Howren et al., 2009;
Liu et al., 2012) and depression in cross-sectional settings was
reviewed and retracted. Data were searched and extracted inde-
pendently by two authors (RH and JM), the results were compared
and consensus obtained through discussion. Supplementary Fig. 1
shows the literature search strategy.2.2. Selection criteria
The immune markers evaluated in this study were selected
based on their effects on the development of sickness behaviour
(IL-1b and TNF-a) (Dantzer, 2001; Dantzer et al., 2008) and previ-
ous meta-analyses suggesting possible associations of peripheral
levels of IL-1, (Howren et al., 2009) TNF-a, (Dowlati et al., 2010;
Liu et al., 2012) and IL-6, (Dowlati et al., 2010; Hiles et al.,
2012b; Liu et al., 2012) CRP (Howren et al., 2009) with depression.
Previous meta-analyses did not support the involvement of IL-10,
(Dowlati et al., 2010; Hiles et al., 2012b; Liu et al., 2012) IL-4,
(Dowlati et al., 2010; Liu et al., 2012) IL-8, (Dowlati et al., 2010;
Liu et al., 2012) IL-2, (Dowlati et al., 2010; Liu et al., 2012) or
IFN-c (Dowlati et al., 2010; Liu et al., 2012) in depression, and
therefore these cytokines were not included in this analysis.
Speciﬁc inclusion criteria were (1) measurement of unstimu-
lated cytokines from the blood; (2) comparison of adult patients
with MDD and psychiatrically healthy controls; (3) use of struc-
tured clinical assessments (SCID or MINI) based on
DSM-III/DSM-IV criteria to verify unipolar MDD; (4) incorporation
of study subjects without major physical illness (i.e. diabetes, heart
disease, cancer etc.) at the time of assessment. Studies focusing on
pregnant women, postpartum depression or including patients
with metabolic syndrome were excluded from the meta-analysis,
whereas studies targeting patients with stable medical conditions,
such as hypertension were included. Studies where participants
used any medications at the time of blood sampling were referred
to as ‘‘subjects using medication’’. Individuals that had undergone a
washout period from antidepressants before entering the study or
at the time of immune assessments were referred to as ‘‘subjects
not using antidepressant medication’’. The median washout period
in the included studies was 4 weeks with a range between 1 week
and 3 months (Supplementary Table 3).2.3. Quality assessment
This meta-analysis was conducted according to PRISMA guide-
lines (Moher et al., 2009). For evaluation of the quality of included
studies, we used the Newcastle-Ottawa quality assessment scale
(NOS) for case-control studies (Wells et al., 2009) In this method,
each study can obtain a maximum of 9 points in three categories;
selection of study participants (adequate deﬁnition, validation and
representativeness of cases and controls), comparability of cases
and controls, and the ascertainment of exposure (Supplementary
Table 1). In line with the recommendations of the Meta-Analysis
of Observational Studies, (Stroup et al., 2000), we performed a sen-
sitivity analysis excluding those studies with poor quality (NOS
score < 6). We also performed an additional quality analysis using
the score of 7 as the cut-off value.
2.4. Data synthesis
The statistical package Comprehensive Meta-analysis (version
2) was used for data analysis. Effect sizes were calculated using
standardised mean differences (Cohen’s d) from mean (±SD) con-
centrations of each immune marker measured in the blood of
MDD patients and non-depressed controls. If concentrations of
immune markers were not reported, we extracted the effect size
from exact p-values and sample size (Dahl et al., 2014; Euteneuer
et al., 2011; Hornig et al., 1998; Li et al., 2013). When relevant data
were not reported, (Grassi-Oliveira et al., 2009; Maes et al., 1995b;
Weinstein et al., 2010; Yang et al., 2007) we ﬁrst contacted the
authors for assistance and if not successful, retrieved values from
graphs using DataThief III, version 1.6. (Tummers et al., 2008).
A cumulative meta-analysis was performed by sorting of the
included studies according to the date of publication. The p-values
represent the summary statistics of all incorporated studies (rather
than p-values for independent studies), enabling the inspection of
the contribution of each new study to the overall effect estimate.
Due to the variation in effect sizes across studies and to achieve
generalisation of the results, a random-effects model was used in
the analysis of total data and in the meta-regression.
Random-effects models take into account both within- and
between-study variability, and provide a more conservative esti-
mate of effect sizes than can be obtained with the ﬁxed-effect
models. Heterogeneity across studies was assessed using
Cochrane’s Q and p < 0.10 was considered as signiﬁcant. The I2
index < 25% was deﬁned as ‘low’, 50% as ‘moderate’ and 75% ‘high’
heterogeneity (Higgins et al., 2003). Publication bias was examined
using Egger’s regression intercept and Begg and Mazumdar’s rank
correlation. We used four criteria to determine whether further
research conducted in the same manner is likely to be needed to
conﬁrm the conclusion: (1) the association has reached statistical
signiﬁcance several years ago and the effect size has remained
unchanged after the addition of more recent studies; (2) in the
total evidence, there is very little heterogeneity in study-speciﬁc
estimates; (3) any subgroup differences are small; and (4) publica-
tion bias is an unlikely explanation for the ﬁndings.
Potential covariates were selected, based on earlier reports
showing associations of age, gender and BMI with both inﬂamma-
tory markers and depression (Hiles et al., 2012b; Howren et al.,
2009; Liu et al., 2012). When data were presented separately for
different subgroups of patients, we computed a combined effect
size for ﬁnal analysis. Mean age of study population (>40 vs.
640 years), gender (>50% vs. 650% of study subjects female), sam-
ple size (over 50 subjects was deﬁned as large), sample quality (P6
was deﬁned as high quality), patient type (inpatient vs. outpatient)
and BMI (controlled for vs. not controlled) were used as categorical
effect modiﬁers in the subgroup analyses. In the sensitivity analy-
sis, we performed meta-analyses using only high quality studies
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studies including only participants not using antidepressants at
the time of blood sampling.3. Results
After excluding duplicates, reviews, animal studies and
non-relevant studies, the full texts of remaining articles (n = 209)
were inspected in detail (Supplementary Fig. 1). Articles were
excluded when a diagnosis of MDD was not made according to
Diagnostic and Statistical Manual of Mental Disorders (DSM) crite-
ria and when studies did not employ sufﬁciently exact and speciﬁc
patient exclusion criteria (N = 93). We excluded studies which had
included patients with minor depression (N = 1) and bipolar disor-
der (N = 2) in addition to MDD patients. Studies were also excluded
if patients suffered from a signiﬁcant comorbid disease (N = 31), or
if the study lacked a proper control group (N = 16), if inﬂammatory
marker measurements had been assayed in ﬂuids other than
venous blood (N = 5) or if in vitro stimulated cytokines had been
used to assess immune function (N = 3). In total, 58 articles met
the inclusion criteria: 20 studies for CRP (Cizza et al., 2009;
Dome et al., 2009; Frodl et al., 2012; Häfner et al., 2008; Hornig
et al., 1998; Hughes et al., 2012; Joyce et al., 1992; Karlovic et al.,
2012; Keri et al., 2014; Kling et al., 2007; Lanquillon et al., 2000;
O’Donovan et al., 2013; Piletz et al., 2009; Rothermundt et al.,
2001; Rudolf et al., 2014; Sluzewska et al., 1996; Thomas et al.,
2005; Tuglu et al., 2003; Weinstein et al., 2010; Zahn et al.,
2013), 31 studies for IL-6 (Basterzi et al., 2005; Carvalho et al.,
2013; Dahl et al., 2014; Dhabhar et al., 2009; Dunjic-Kostic et al.,
2013; Euteneuer et al., 2011; Fitzgerald et al., 2006; Fornaro
et al., 2011; Frodl et al., 2012; Hennings et al., 2013; Hughes
et al., 2012; Kagaya et al., 2001; Karlovic et al., 2012; Keri et al.,
2014; Leo et al., 2006; Maes et al., 1997, 1995a,b; Mikova et al.,
2001; Motivala et al., 2005; O’Brien et al., 2007; O’Donovan et al.,
2013; Pavon et al., 2006; Pike and Irwin, 2006; Rudolf et al.,
2014; Simon et al., 2008; Sluzewska et al., 1996; Voderholzer
et al., 2012; Weinstein et al., 2010; Yang et al., 2007; Yoshimura
et al., 2010), 31 studies for TNF-a (Dahl et al., 2014; Diniz et al.,
2010b; Dome et al., 2009; Dunjic-Kostic et al., 2013; Eller et al.,
2009, 2008; Euteneuer et al., 2011; Fitzgerald et al., 2006;
Fornaro et al., 2013; Grassi-Oliveira et al., 2009; Hornig et al.,
1998; Huang and Lee, 2007; Hughes et al., 2012; Kagaya et al.,
2001; Karlovic et al., 2012; Leo et al., 2006; Li et al., 2013; Maes
et al., 2012a,b; Mikova et al., 2001; Narita et al., 2006; O’Brien
et al., 2007; O’Donovan et al., 2013; Pavon et al., 2006; Piletz
et al., 2009; Schmidt et al., 2014; Simon et al., 2008; Sutcigil
et al., 2007; Tuglu et al., 2003; Weinstein et al., 2010; Yang et al.,
2007) and 14 studies for IL-1b (Dahl et al., 2014; Diniz et al.,
2010a; Fornaro et al., 2013; Hernandez et al., 2008, 2013; Huang
and Lee, 2007; Hughes et al., 2012; Kagaya et al., 2001; Leo et al.,
2006; Pavon et al., 2006; Piletz et al., 2009; Simon et al., 2008;
Thomas et al., 2005; Yang et al., 2007). Supplementary Table 2 pre-
sents the descriptive and quality data of each study and
Supplementary Table 3 shows the speciﬁc inclusion and exclusion
criteria used in these studies.3.1. Cumulative meta-analyses
3.1.1. Interleukin 6
The cumulative meta-analysis showed a medium-sized associa-
tion between IL-6 and MDD (N = 31, combined d = 0.54, 95%
CI = 0.40–0.69, total N(MDD) = 1045, total N(non-MDD) = 977)
(Fig. 1). A statistically signiﬁcant association (p < 0.0001) was ﬁrst
achieved in 2006, and this result has remained unchanged after 23
more studies published between the years 2006 and 2014.Moderate heterogeneity between studies was detected (Q = 68.5,
p < 0.0001, I2 = 56.2%), but there was no apparent publication bias:
Begg and Mazumdar’s tau 0.16 (p = 0.21), Egger’s regression inter-
cept 1.13 (p = 0.30).
3.1.2. C-reactive protein
There was a medium-sized association between CRP and MDD
(N = 20, combined d = 0.47; 95% CI = 0.28–0.65, total
N(MDD) = 746, total N(non-MDD) = 679) (Fig. 2). Statistical signiﬁ-
cance (p < 0.0001) was achieved after 14 studies, and the associa-
tion did not change after supplementing with six more studies.
Heterogeneity between studies was moderate (Q = 51, p < 0.0001,
I2 = 62%) and no apparent publication bias was notiﬁed (Begg and
Mazumdar’s tau 0.06 (p = 0.72), Egger’s regression intercept 1.02
(p = 0.47).
3.1.3. Tumour necrosis factor a
The pooled evidence showed increased blood levels of TNF-a in
MDD patients (N = 31, combined d = 0.40, 95% CI = 0.15–0.65, total
N(MDD) = 1214, total N(non-MDD) = 1262) (Fig. 3). The effect
reached statistical signiﬁcance (p < 0.05) after 14 studies in 2009
and the size of the association did not substantially change after
the publication of 17 additional articles. Heterogeneity in
study-speciﬁc effect estimates was high (Q = 254, p < 0.0001,
I2 = 88%), suggesting that systematic differences existed between
studies. There was no apparent publication bias (Begg and
Mazumdar’s tau 0.22 (p = 0.08), Egger’s regression intercept 2.91
(p = 0.12).
3.1.4. Interleukin 1b
IL-1b was not associated with MDD (N = 14, combined d for all
studies = 0.05, 95%CI = 0.57–0.48, total N(MDD) = 491, total
N(non-MDD) = 509) (Fig. 4). There was extensive heterogeneity
between studies (Q = 197, p < 0.0001, I2 = 93%), but no publication
bias (Begg and Mazumdar’s tau 0.09 (p = 0.66), Egger’s regression
intercept was 0.25 (p = 0.96).
3.2. Additional analyses
3.2.1. Sensitivity analyses
When only high quality studies (NOS-scoreP 6) were included
in the analysis, the association between IL-6 and MDD remained
statistically signiﬁcant and stable after completion of the ﬁrst ﬁve
studies (N = 21 studies, d = 0.60, 95%CI = 0.42–0.78, total
N(MDD) = 781, total N(non-MDD) = 711, p < 0.0001) (Table 1).
Including only subjects not using antidepressants decreased the
total number of studies to 16, but the association remained strong
and statistically signiﬁcant after the publication of 11 recent stud-
ies (d = 0.65, p < 0.0001) (Supplementary Fig. 2A). Using the alter-
native cut-off score P7 for high quality revealed that the
association had remained signiﬁcant and unaltered since the pub-
lication of the ﬁrst four studies (N = 8, d = 0.65, p < 0.0001).
With respect to CRP, exclusion of lower quality studies
(NOS-score < 6) conﬁrmed the positive association with MDD:
N = 10, d = 0.69, 95%CI = 0.43–0.95, total N(MDD) = 395, total
N(non-MDD) = 321) (Table 1). Further exclusions of the studies
allowing the use of medications during the blood draw sampling
led to even increased effect size estimates (d = 0.88, p < 0.0001).
These associations have remained unaltered since 1996 to 2014
after completion of seven additional studies (Supplementary
Fig. 2B). The use of the cut-off scoreP7 for quality assessment left
only ﬁve studies for analysis; however, the association still
remained statistically signiﬁcant (d = 0.69, p = 0.002).
In the analysis of high quality studies, the association between
TNF-a and MDD weakened and changed to being statistically
non-signiﬁcant (N = 18, d = 0.28, p = 0.09, 95%CI = 0.04–0.59 total
Fig. 1. Cumulative meta-analysis for IL-6 levels and major depressive disorder.
Fig. 2. Cumulative meta-analysis for CRP levels and major depressive disorder.
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sion of studies permitting the concomitant use of medications
resulted in a positive but statistically unstable association between
TNF-a and MDD (N = 12, d = 0.57, p = 0.004) (Supplementary
Fig. 2C).
Our sensitivity analysis conﬁrmed the lack of association
between IL-1b and MDD in the high quality (NOS > 6) studies
restricted to patients free of antidepressant medication (N = 9,
d = 0.36, p = 0.29) (Supplementary Fig. 2D).
3.2.2. Subgroup differences
Age, gender, BMI, medication use, study size or patient type did
not modify the association between IL-6 and MDD (Table 1). TNF-awas signiﬁcantly related to MDD in studies restricted to
antidepressant-free subjects (p = 0.001), studies including younger
participants (age < 40) (p = 0.001), as well as those not controlling
for BMI (p = 0.006) and including more female than male study
subjects (p = 0.004). The association between IL-1b and MDD was
statistically signiﬁcant only in older patients (p < 0.0001).
Majority of studies (N = 38, 66%) reported depressive symptoms
being severe or very severe (Supplementary Table 4). Severe
depression was more strongly associated with IL-6, CRP and
TNF-a compared to moderate depression (Table 1).
A meta-regression revealed that a higher mean age was associ-
ated with weaker associations between TNF-a and MDD (p = 0.01),
and stronger associations between IL-1b and MDD (p = 0.007).
Fig. 3. Cumulative meta-analysis for TNF-a levels and major depressive disorder.
Fig. 4. Cumulative meta-analysis for IL-1b levels and major depressive disorder.
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between IL-6 and MDD with increased mean age (p = 0.06). No sig-
niﬁcant associations between immune markers and HAMD score
(an indicator of the severity of symptoms) were found.
3.2.3. Other Axis I/II disorders and depression subtypes
Information on other Axis I or Axis II diagnoses, such as gener-
alised anxiety disorders or any anxiety or psychotic disorders,
panic disorder, phobia, obsessive–compulsive disorder,
post-traumatic stress disorder, schizophrenia or bipolar disorder,
had been included in 27 (47%) of the 58 studies (Supplementary
Table 4). Fifteen (26%) studies did not assess or report other Axis
I or Axis II disorders and 26% excluded all patients with any other
Axis I or Axis II disorder other than MDD. Thirteen studies (22%)
excluded patients with psychotic features, 10 (17%) with bipolar
disorder and 4 (7%) with comorbid anxiety symptoms.
Most studies (72%) did not include information on the different
subtypes of MDD. MDD with melancholic features had beeninvestigated in 10 (17%) studies, atypical and
suicidal/non-suicidal MDD in 3 (5%) and treatment-resistant
MDD in 5 (9%) studies. Given the large variability in
study-speciﬁc inclusion and exclusion criteria for other Axis I/II
disorders and a small number of studies specifying different
depression subtypes, we could not assess the role of these covari-
ates on the depression-inﬂammation relation.3.2.4. Pharmacotherapy
From the 39 studies not allowing antidepressant medication
during the inﬂammatory marker assessments, 35 (90%) speciﬁed
the use of SSRIs and/or other classes of antidepressants as an exclu-
sion criterion and four studies (10%) used the term ‘‘medication
free’’ as their inclusion criterion (Supplementary Table 4).
Fourteen studies (36%) had speciﬁed the concomitant use of
antidepressants and other psychotropic medications (including
anxiolytics, antipsychotics and/or mood stabilizers) as exclusion
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and anti-inﬂammatory medications.
3.2.5. Lifestyle factors
Twenty-two (38%) studies included smokers, 16 (28%) studies
did not give information on substance use (smoking, drinking or
drug use) and 24 (41%) had excluded patients with drug abuse or
substance dependence (Supplementary Table 4). Since only 6
(10%) of studies had excluded subjects who were smokers, the role
of smoking on inﬂammation–depression associations could not be
veriﬁed. In the high-quality studies with subjects not using antide-
pressants, 12/16 (75%) for IL-6 and 5 of 7 studies (71%) for CRP had
excluded patients with previous/current substance abuse.
3.2.6. Other potential covariates
Other covariates available in some of the studies, such as the
number of depression episodes and the duration and age of onset
of depressive disorder (Supplementary Table 3), were not consid-
ered in the current meta-analysis. The effect of physical comorbid-
ity on the inﬂammatory marker–depression association could not
be tested given the nature of the available information.4. Discussion
Using cumulative meta-analysis, we sought to determine the
strength of the totality of evidence and the year when the associa-
tion between speciﬁc immune markers and major depressive dis-
order ﬁrst reached statistical signiﬁcance. In addition, we
explored the effect of subsequent studies on the overall effect size
enabling us to evaluate whether new studies are likely to change
these associations (Clarke et al., 2014). We found strong support
for higher circulating IL-6 concentrations in patients with major
depression in comparison to non-depressive individuals. This asso-
ciation has remained essentially unchanged from 2006 until the
present date and including 23 additional studies. Similarly, the
CRP–major depression relationship is robust and has been unal-
tered since 2012 after addition of six more recent publications.
Nonetheless, these additional data, while having only a marginal
effect on the overall effect size estimate, have narrowed the 95%
conﬁdence intervals. Additional sensitivity analyses incorporating
only high-quality studies of subjects not receiving antidepressant
drug treatment further strengthened these relationships, evidence
that the observed associations are robust and unlikely to change
should new studies be conducted using similar designs.
Our ﬁndings on IL-6 and CRP are in agreement with preclinical
data showing a plausible role of IL-6 in the pathology of
depressive-like behaviour (Chourbaji et al., 2006; Sukoff Rizzo
et al., 2012), predictive associations of IL-6 and CRP with the future
development of mood disorders (Gimeno et al., 2009; Khandaker
et al., 2014; Kivimaki et al., 2014; Virtanen et al., 2015;
Wium-Andersen et al., 2013), evidence of dose–response relation-
ships (Kivimaki et al., 2014) and associations of these inﬂamma-
tory markers with therapeutic response to antidepressants and
ketamine (Cattaneo et al., 2013; Dahl et al., 2014; Hiles et al.,
2012a; Yang et al., 2014). Our ﬁndings also conﬁrm those reported
in previous meta-analyses which included a smaller number of
cross-sectional (Dowlati et al., 2010; Liu et al., 2012) and longitu-
dinal studies (Valkanova et al., 2013) on IL-6 and CRP. Subgroup
analysis showed that the associations of IL-6 and CRP concentra-
tions with major depression remained relatively stable when
assessing the effect of age, gender, BMI, study size or study quality
on overall effect estimate.
The association between TNF-a and major depression, although
the volume of existing research for this inﬂammation marker is
equal to or even greater than that examining IL-6 or CRP, was less
212 R. Haapakoski et al. / Brain, Behavior, and Immunity 49 (2015) 206–215convincing: the overall effect size was smaller, the ﬁndings in sen-
sitivity and subgroup analyses were less consistent and, impor-
tantly, the association was attenuated in higher quality studies
and studies controlling for obesity. These results may result from
a weaker association, failure to properly control for confounding
factors (Hiles et al., 2012b) or difﬁculties in measuring accurately
this inﬂammatory marker. In all these cases, improvements in
research protocols and study designs, rather than simply more
research conducted in a similar manner, are needed.
Furthermore, the divergent effects of anti-TNF-a therapy on
depressive symptoms (Kohler et al., 2014) point to the existence
of potential confounders moderating the strength of the associa-
tion between TNF-a and major depression.
Aggregate data from the 15 studies on IL-1b did not convinc-
ingly conﬁrm or refute an association with major depression. The
summary effect estimate based on these 15 studies was completely
null, whereas for CPR and IL-6, the summary estimate had reached
statistical signiﬁcance after the completion of 14 or 8 studies,
respectively. Elevated IL-1b levels in subjects with major depres-
sion, in comparison to non-depressive controls, were observed
only in studies including subjects older than 40 years of age and
studies rated as lower quality. The lack of a robust association
between IL-1b and major depression might be partly attributable
to measurement issues, as the concentrations of IL-1b are very
low in blood and therefore more difﬁcult to determine accurately
using conventional immunological assays. Further research on a
range of IL-1-family proteins (e.g. IL1Ra, soluble ILRII or soluble
ST2), in addition to IL-1b, could increase our understanding of
the role of IL-1 in major depression.
In general, the strength of the association between inﬂamma-
tion and major depression may vary depending on methods of
depression diagnosis, sample characteristics, and control for con-
founders. For example, the relationships between venous blood
levels of IL-6, CRP and depression have been weaker in studies
using self-reported instruments rather than clinical diagnosis to
ascertain depression, in community-based subjects compared to
clinical samples, and when participants treated with antidepres-
sants at the time of immune assessment have been included in
the analysis (Hannestad et al., 2011; Hiles et al., 2012a,b;
Howren et al., 2009). Furthermore, it is plausible that different sub-
types of depressive disorder may be associated with different
inﬂammatory proﬁles (Dunjic-Kostic et al., 2013; Kaestner et al.,
2005; Karlovic et al., 2012). Similarly, chronic diseases, severity
of depressive symptoms and comorbid psychiatric disorders may
affect the magnitude of the associations between inﬂammation
and major depression (Hiles et al., 2012b; Howren et al., 2009;
Irwin and Miller, 2007; Stuart and Baune, 2012; Van der Kooy
et al., 2007). The majority of major depressive patients included
in our meta-analysis could be classiﬁed as severely or very severely
depressed; IL-6, CRP and TNF-a were more strongly associated
with severe than non-severe forms of depression. In an attempt
to minimise the effect of chronic diseases and medications on
immune-depression associations, we only included patients free
of major chronic diseases and antidepressant use at the time of
blood sampling in our sensitivity analysis. These analyses revealed
that the association between IL-6, CRP and major depression
remained strong and unaltered in studies of higher quality and
antidepressant-free patients.
Compared to the most recent meta-analyses on this topic
(Dowlati et al., 2010; Liu et al., 2012), our cumulative
meta-analysis includes seven additional articles on IL-6 and eight
on TNF-a that employed subjects not on antidepressants treatment
and free of major physical diseases. We also included 10 additional
studies on IL-6 and 13 on TNF-a allowing the use of medications
and investigated those studies as a subgroup. One previous
meta-analysis assessing the association between CRP, IL-6 anddepression employed more relaxed inclusion criteria and sample
material which may partially explain the smaller overall effect size
estimates described in that study (CRP, d = 0.15 and IL-6, d = 0.25)
(Howren et al., 2009). The meta-analysis conducted by Hiles et al.
(2012b) found that the association between IL-6 and depression
did not signiﬁcantly differ between smokers and non-smokers
and samples analysed by different processing techniques.
However, in agreement with our cumulative meta-analysis and
previous standard meta-analyses, inclusion of patients using psy-
chotropic medication and the lack of adjustment for over-
weight/obesity resulted in slightly larger effect size estimates
between the levels of CRP, IL-6 and depression (Hiles et al.,
2012b; Howren et al., 2009).
The observed heterogeneity between study-speciﬁc effect esti-
mates was either high (TNF-a and IL-1b) or moderate (IL-6 and
CRP). While some of the subgroup analyses, e.g. studies including
older subjects or patients with moderate depression (IL-1b),
younger participants (CRP) or more men (IL-6) were associated
with reduced overall heterogeneity between studies, none of these
factors signiﬁcantly affected the overall associations. On the other
hand, heterogeneity remained high (I2 > 79%) in all additional anal-
yses examining the relationship between TNF-a and major depres-
sion. These results indicate that some other undeﬁned factors may
be modifying the observed associations. For example, genetic vari-
ations and brain abnormalities have been proposed to be associ-
ated with depression-related immune activation (Bufalino et al.,
2013; Savitz et al., 2013) and developmental inﬂuences, such as
childhood trauma, may also be linked to increased vulnerability
to develop psychiatric disorders in later life via inﬂammatory pro-
cesses (Tursich et al., 2014). Furthermore, it is possible that inﬂam-
mation is only linked to some speciﬁc characteristic symptoms of
major depression. Exploration of the role of gene-environment
interactions and other potential moderators affecting on the
strength and the nature of immune–depression relationships
remains a challenge for future investigators.
The limitations of the current study need to be taken into
account when interpreting the results. First, when determining
the co-occurrence of inﬂammation and major depression, we
focused on a cross-sectional association based on one-time assess-
ments of inﬂammatory markers, although these measurements
cannot reliably distinguish between chronic and acute inﬂamma-
tion. The few previous studies assessing chronic inﬂammation have
revealed stronger associations with mental health when inﬂamma-
tion is determined using repeated measurements rather than only
one measurement (Gimeno et al., 2009; Kivimaki et al., 2014). If
this also applies to the situation with major depression, then the
present data may, if anything, underestimate the role of the speci-
ﬁc inﬂammation markers in major depressive disorders. Due to the
lack of longitudinal studies using repeated immune assessments to
investigate the role of inﬂammation in clinically depressed
patients, the strength of these associations remains uncertain.
Second, the lack of well-designed and adequately controlled
studies (none of the included studies received a maximum quality
score of 9% and 41% of all studies were scored as low quality, scores
0–5) highlight the need for future studies with improved study
designs and more comprehensive control for confounding vari-
ables. Third, as only four studies on IL-6 and seven on TNF-a had
differentiated data for different subtypes of major depression
(e.g. melancholic, atypical, suicidal, recurrent and/or
treatment-resistant depression) we could not include a more
detailed analysis assessing the association of subtypes of major
depressive disorders with circulating inﬂammatory markers.
Fourth, comparison of major depression patients with and without
comorbid conditions with healthy controls may inﬂate the
observed group differences because a number of comorbid condi-
tions may increase both inﬂammation and depression. Therefore,
R. Haapakoski et al. / Brain, Behavior, and Immunity 49 (2015) 206–215 213future studies investigating the association between inﬂammation
and major depression should pay more attention to ensure that
they control properly for the inﬂammatory effects of physical
conditions.
5. Conclusions
Cumulative meta-analyses are important in collating the total-
ity of data, potentially helping researchers and funders to make
informed decisions about the sufﬁciency of evidence and to set pri-
orities for new studies. Ideally, this will contribute to a faster accu-
mulation of knowledge and reduced costs and effort by preventing
unnecessary research. Our cumulative meta-analysis of four
inﬂammatory markers sought to bring together the ﬁndings from
studies on the co-occurrence of elevated systemic levels of inter-
leukins 6 and 1b, tumour necrosis factor a and C-reactive protein
and major depressive disorders. The strong evidence of increased
circulating concentrations of interleukin-6 and C-reactive protein
in patients with major depressive disorder but not on antidepres-
sant medication compared with non-depressed individuals con-
ﬁrms the cross-sectional association between inﬂammation and
major depression. Peripherally administered IL-6 has been shown
to cross the blood–brain barrier (Banks et al., 1994), suggesting
that immunomodulatory studies aimed at reducing IL-6 in sub-
groups of patients with an elevated inﬂammatory proﬁle could
have potential in the treatment of patients with depression and
enhanced levels of inﬂammation. While concentrations of TNF-a
and IL-1b appeared to be elevated in certain subgroups of patients,
the role of confounding factors, such as age and obesity, should be
taken into account when planning future research on these
immune markers. Furthermore, future studies are needed to mon-
itor symptomatic presentations, classify depressive symptoms and
control more comprehensively for confounders potentially inter-
fering with immune–depression relations (including lifestyle fac-
tors, other psychiatric disorders, comorbid physical conditions
and medications used at the time of assessments). More attention
should also be paid to the accuracy of the measurement of IL-1b.
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